912762-33-5

Usage

Uses

Used in Pharmaceutical Research:
[2-(3-METHOXY-PHENYL)-2-OXO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER is used as a reagent for pharmaceutical research to aid in the development of new drugs. Its unique structure allows for the creation of various pharmaceutical products that can potentially address a range of health conditions.
Used in Organic Synthesis:
In the field of organic synthesis, [2-(3-METHOXY-PHENYL)-2-OXO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER is used as a reagent to facilitate the synthesis of complex organic molecules. Its versatile structure enables the formation of different chemical bonds and reactions, contributing to the creation of a wide array of organic compounds.
Used in Drug Development:
[2-(3-METHOXY-PHENYL)-2-OXO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER is used as a key component in drug development, where its properties can be harnessed to design and synthesize novel therapeutic agents. Its potential applications in this area make it a valuable asset for researchers working on the next generation of pharmaceuticals.
Used in the Production of Pharmaceutical Products:
This chemical compound is also utilized in the production of various pharmaceutical products. Its incorporation into the manufacturing process can enhance the efficacy, safety, or stability of the final product, making it an important component in the pharmaceutical industry.

InChI:InChI=1/C14H19NO4/c1-14(2,3)19-13(17)15-9-12(16)10-6-5-7-11(8-10)18-4/h5-8H,9H2,1-4H3,(H,15,17)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 189506-47-6 2-amino-1-(3-methoxyphenyl)ethan-1-one 
• 5000-65-7 2-bromo-3'-methoxyacetophenone 
• 398489-26-4 tert-butyl 3-oxoazetidine-1-carboxylate 
• 2398-37-0 3-methoxyphenyl bromide 
• 24037-72-7 2-amino-1-(3-methoxyphenyl)ethan-1-one hydrochloride 

Downstream Products

• 912762-53-9 C₁₄H₂₀N₂O₄ 

Relevant academic research and scientific papers

BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR

The invention relates to a benzopyrazole compound used as RHO kinase inhibitor, a pharmaceutical composition and uses thereof for preparing an RHO kinase inhibiting drug, and more specifically to said compound of formula (I-1), a pharmaceutically acceptable salt and isomer thereof.

Oxidative Deconstruction of Azetidinols to α-Amino Ketones

A silver-mediated synthesis of α-amino ketones via the oxidative deconstruction of azetidinols has been developed using a readily scalable protocol with isolated yields up to 80percent. The azetidinols are easily synthesized in one step and can act as protecting groups for these pharmaceutically relevant synthons. Furthermore, mechanistic insights are presented and these data have revealed that the transformation is likely to proceed through the β-scission of an alkoxy radical, followed by oxidation and C-N cleavage of the resulting α-amido radical.

Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors

Inhibition of sphingosine-1-phosphate lyase has recently been proposed as a potential treatment option for inflammatory disorders such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. In this report we describe our hit-to-lead evaluation of the isoxazolecarboxamide 6, a high-throughput screening hit (in vitro IC50 = 1.0 μM, cell IC50 = 1.8 μM), as a novel S1P lyase inhibitor. We were able to establish basic structure-activity relationships around 6 and succeeded in obtaining X-ray structural information which enabled structure-based design. With the discovery of 28, enzyme activity was quickly improved to IC50 = 120 nM and cell potency to IC50 = 230 nM. The main liability in the established isoxazolecarboxamide hit series was determined to be metabolic stability. In particular we identified that future lead-optimization efforts to overcome this problem should focus on blocking the N-dealkylation on the secondary amine.